A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer
The purpose of this study is to find the best dose to use of an investigational drug called MK-2206 when given in combination with Lapatinib that can be safely given for breast cancer treatment. Participants in this study have a breast tumor that is not responding to standard therapy, or there is no therapy available to treat this cancer. There are two parts to this study: the first part is to test the combination of MK-2206 and Lapatinib in the treatment of advanced or metastatic solid tumors. In the second part of the study, only subjects with locally advanced and unresectable (unable to be removed by surgery) or metastatic HER2+ breast cancer will be able to enroll. During the second part of the study, the effectiveness of MK-2206 and Lapatinib will be studied.
Back to Clinical Trials list